Chih‐Yang Hsu

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Alan S. Go, Glenn M. Chertow, Dongjie Fan et al. · ACC Current Journal Review · 2004 · 185 citations

Glomerular Disease, Glomerulonephritis, Hemodialysis +15

Physiological changes during hemodialysis in patients with intradialysis hypertension

Kang‐Ju Chou, P.-T. Lee, Chien‐Liang Chen et al. · Kidney International · 2006 · 139 citations

Hemodialysis, Hypertension, Renal Disease +8

Cerebrospinal Fluid Mechanics and Its Coupling to Cerebrovascular Dynamics

Andreas A. Linninger, Kevin Tangen, Chih‐Yang Hsu et al. · Annual Review of Fluid Mechanics · 2015 · 136 citations

Pediatric Hydrocephalus, Fluid Mechanics, Brain Lesion +18